---
title: "Positive Phase 1 results for SEP-631 show dose-dependent inhibition of skin wheal formation, complete at 10mg/day.205 characters."
description: "The new drug SEP-631 has shown strong and dose-dependent inhibition of skin wheal formation induced by icatibant. At doses as low as 10 mg taken once daily, complete inhibition was achieved."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277360762.md"
published_at: "2026-03-01T14:46:12.000Z"
---

# Positive Phase 1 results for SEP-631 show dose-dependent inhibition of skin wheal formation, complete at 10mg/day.205 characters.

> The new drug SEP-631 has shown strong and dose-dependent inhibition of skin wheal formation induced by icatibant. At doses as low as 10 mg taken once daily, complete inhibition was achieved.

The new drug SEP-631 has shown strong and dose-dependent inhibition of skin wheal formation induced by icatibant. At doses as low as 10 mg taken once daily, complete inhibition was achieved.

### Related Stocks

- [SEPN.US - Septerna](https://longbridge.com/en/quote/SEPN.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/en/news/277123919.md) |
| Protara falls after mid-stage trial data for lead asset in bladder cancer | Protara Therapeutics (TARA) shares fell approximately 22% following the release of interim data from a mid-stage trial f | [Link](https://longbridge.com/en/news/276778182.md) |
| Dror Ortho-Design, Inc. SEC 10-K Report | Dror Ortho-Design, Inc. has released its annual 10-K report, detailing its financial performance and strategic initiativ | [Link](https://longbridge.com/en/news/277226243.md) |
| Soleno Therapeutics reports FY profit for 2025 | Soleno Therapeutics reported a profitable FY 2025 with a net income of $20.9 million, driven by Q4 revenue of $91.7 mill | [Link](https://longbridge.com/en/news/276938001.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/en/news/277046688.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.